Related Experiment Video
Updated: May 22, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Soluble CD146 and APS: a potential biomarker of obstetrical complications?
E Kaspi1, M B Chabaud, F D George
1UMR-S 608, Aix-Marseille University, Faculté de Pharmacie, France.
Insights
Soluble CD146 (sCD146) may serve as a novel biomarker for obstetric antiphospholipid syndrome (APS). Elevated sCD146 levels are linked to recurrent fetal losses in women with APS.
Area of Science:
- Obstetrics and Gynecology
- Immunology
- Vascular Biology
Background:
- Obstetric antiphospholipid syndrome (APS) is a challenging clinical subset of APS, necessitating new diagnostic markers.
- Soluble CD146 (sCD146) is an endothelial biomarker involved in inflammatory processes, including monocyte transmigration.
- sCD146 exhibits chemotactic and angiogenic properties and shows physiological variations with age and sex.
Purpose of the Study:
- To investigate the potential of soluble CD146 (sCD146) as a biomarker in obstetric antiphospholipid syndrome (APS).
- To explore the association between sCD146 levels and adverse pregnancy outcomes, specifically recurrent fetal losses.
Main Methods:
- Detection of soluble CD146 (sCD146) levels in human sera.
- Analysis of sCD146 variations in relation to physiological factors (age, sex) and clinical conditions.
Main Results:
- Soluble CD146 (sCD146) levels exhibit physiological variations.
- Significantly higher sCD146 levels were observed in women with a history of recurrent fetal losses.
Conclusions:
- Soluble CD146 (sCD146) may represent a promising circulating biomarker for obstetric antiphospholipid syndrome (APS).
- Elevated sCD146 levels are associated with recurrent fetal losses, suggesting its role in the pathophysiology of obstetric APS.
Abstract:
Obstetric antiphospholipid syndrome (APS) seems to be a clinical subset of classical APS, for which the search for new markers is still challenging. Soluble CD146 (sCD146) constitutes a circulating endothelial biomarker. sCD146 is involved in the inflammatory response by promoting monocyte transmigration and displays chemotactic and angiogenic properties on endothelial cells. Its detection in human sera reveals physiological variations related to age and sex. A wide variation of sCD146 has been reported in several conditions. In particular, sCD146 levels are significantly higher in women presenting a history of recurrent fetal losses.
